Corient Private Wealth LLC Sells 1,800 Shares of Balchem Co. (NASDAQ:BCPC)

Corient Private Wealth LLC decreased its stake in Balchem Co. (NASDAQ:BCPC) by 0.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 254,192 shares of the basic materials company’s stock after selling 1,800 shares during the period. Corient Private Wealth LLC owned approximately 0.78% of Balchem worth $41,432,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. State Street Corp grew its position in Balchem by 1.0% in the 3rd quarter. State Street Corp now owns 1,234,226 shares of the basic materials company’s stock worth $217,224,000 after purchasing an additional 12,006 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Balchem by 3.1% in the third quarter. Geode Capital Management LLC now owns 928,904 shares of the basic materials company’s stock valued at $163,514,000 after buying an additional 27,979 shares during the period. Geneva Capital Management LLC increased its stake in Balchem by 5.1% during the fourth quarter. Geneva Capital Management LLC now owns 819,746 shares of the basic materials company’s stock valued at $133,615,000 after acquiring an additional 39,877 shares during the period. FMR LLC raised its holdings in Balchem by 944.3% in the 3rd quarter. FMR LLC now owns 497,495 shares of the basic materials company’s stock valued at $87,559,000 after acquiring an additional 449,854 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Balchem by 1.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 458,986 shares of the basic materials company’s stock worth $80,782,000 after acquiring an additional 7,721 shares during the period. Institutional investors own 87.91% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on BCPC. Sidoti upgraded Balchem to a “hold” rating in a research report on Tuesday, February 25th. HC Wainwright restated a “buy” rating and issued a $190.00 price objective on shares of Balchem in a research note on Monday, February 24th. Finally, StockNews.com lowered shares of Balchem from a “buy” rating to a “hold” rating in a research report on Tuesday, February 25th.

Balchem Price Performance

Shares of BCPC stock opened at $168.46 on Tuesday. The stock’s fifty day simple moving average is $164.07 and its 200 day simple moving average is $169.70. Balchem Co. has a one year low of $137.69 and a one year high of $186.03. The firm has a market cap of $5.48 billion, a price-to-earnings ratio of 42.87, a P/E/G ratio of 4.41 and a beta of 0.63. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.99 and a quick ratio of 1.16.

Balchem (NASDAQ:BCPC) last issued its earnings results on Friday, February 21st. The basic materials company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.11 by ($0.08). The firm had revenue of $240.00 million during the quarter, compared to analyst estimates of $239.96 million. Balchem had a net margin of 13.47% and a return on equity of 11.37%. On average, analysts expect that Balchem Co. will post 4.64 earnings per share for the current fiscal year.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.